beclamide

Beclamide (N-benzyl-3-chloropropionamide) is a small molecule anticonvulsant and sedative agent that was historically used in the management of generalized tonic-clonic seizures and behavior disorders associated with epilepsy. Its pharmacological profile is characterized by the inhibition of the release of excitatory amino acids, specifically D-aspartate, and the inhibition of succinic semialdehyde dehydrogenase (SSADH), an enzyme involved in the degradation of GABA. Additionally, beclamide has demonstrated anti-aggressive properties in animal models, which are thought to be mediated by the modulation of presynaptic serotonin (5-HT) release. While it was studied as an adjunct to neuroleptics in the treatment of schizophrenic psychoses to reduce dosage requirements and side effects, beclamide has largely been superseded by newer antiepileptic drugs in modern clinical practice.

Brand names

NydraneChloraconHibicon

Other names

N-benzyl-3-chloropropionamideN-benzyl3-chloropropionamideN-benzyl 3-chloropropionamideBenzchlorpropamideN-benzyl-beta-chloropropionamideChloraconum